ArticleScientific reports2025
Molecular assessment of the HIV pol gene and use of computational vaccine design targeting Pakistani isolates.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- mRNA vaccine design targeting Merkel cell polyomavirus for immunotherapy of Merkel cell carcinoma.Scientific reports · 2026Article
- Therapeutic modulation of HIV-1 using miRNAs and lncRNAs: from bench to bedside.Virology journal · 2026Review
- Gut microbiome-based strategies for HIV prevention and therapy, current challenges and future prospects.Gut pathogens · 2026Review
- World free HIV: the novel therapeutic approaches for eliminating latent HIV infection.Virology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV) is considered a major threat to human health. The global prevalence of individuals infected with HIV-1 continues to rise. Consequently, the development of an effective immune-stimulatory vaccine has recently garnered significant attention in the field of HIV-1 vaccine formulation. This study conducted a molecular assessment of the Pol region, identifying conserved sequences across our 14 HIV isolates. Utilizing multiple servers and filtering methods, highly effective B-cell epitopes, along with helper T lymphocyte (HTL) and cytotoxic T lymphocyte (CTL) epitopes, were identified. Specifically, five B-cell epitopes, eight CTL epitopes, and twelve HTL epitopes were selected for vaccine development. The resulting vaccine construct comprises 557 amino acids, has a theoretical isoelectric point of 8.98, and a GRAVY score of - 0.785. Codon optimization and in-silico cloning into prokaryotic vectors were performed to enhance expression Escherichia coli hosts. Molecular dynamics simulations confirmed the most stable interaction of the vaccine components with Toll-like receptor 3 (TLR3), while also demonstrating stable interactions with TLR5, TLR7, TLR8, and TLR9, eliciting a robust immunogenic response. The vaccine model effectively activates both humoral and cellular immune responses; however, experimental validation is required to confirm these in silico findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.